Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

150.13
-0.2600-0.17%
Post-market: 150.130.00000.00%19:30 EDT
Volume:163.37K
Turnover:24.69M
Market Cap:2.16B
PE:-30.65
High:154.30
Open:152.75
Low:149.98
Close:150.39
52wk High:161.38
52wk Low:53.30
Shares:14.41M
Float Shares:8.40M
Volume Ratio:0.82
T/O Rate:1.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8978
EPS(LYR):-3.7076
ROE:-46.63%
ROA:-22.05%
PB:9.97
PE(LYR):-40.49

Loading ...

Mizuho Securities Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

TIPRANKS
·
Sep 10

Palvella Therapeutics Names Pediatric Dermatologist James Treat Chief Medical Officer

Reuters
·
Sep 09

Palvella Therapeutics Appoints James R. Treat, M.d., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer

THOMSON REUTERS
·
Sep 09

Palvella Therapeutics Director Makes Eye-Catching Insider Move in Latest Stock Transaction

TIPRANKS
·
Sep 05

Palvella Therapeutics Director Christopher P. Kiritsy Disposes of 313 Common Shares for $49,141

Reuters
·
Sep 05

Palvella Therapeutics CEO to Speak at Cantor Global Healthcare Conference 2026

Reuters
·
Sep 02

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

GlobeNewswire
·
Sep 02

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)

TIPRANKS
·
Sep 01

Palvella Completes Rolling FDA NDA Submission for Qtorin Rapamycin in Microcystic Lymphatic Malformations

Reuters
·
Aug 31

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

THOMSON REUTERS
·
Aug 31

Palvella Therapeutics - Accelerating U.S. Launch Readiness for Potential Qtorin Rapamycin Launch in H1 2027 if Approved

THOMSON REUTERS
·
Aug 31

Palvella Therapeutics COO Kathleen Goin Reports Sale of 4,302 Common Shares Worth $654,184.41

Reuters
·
Aug 21

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)

TIPRANKS
·
Aug 06

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

GlobeNewswire
·
Aug 05

Palvella Therapeutics Charts Clear Path From Data To Launch

TIPRANKS
·
Aug 05

Cumberland Pharmaceuticals Q2 Loss Widens After Apotex Transaction

Reuters
·
Aug 05

Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026

Reuters
·
Aug 05

Niagen Bioscience Q2 Net Sales Fall, Missing Estimates

Reuters
·
Aug 05

Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise

Reuters
·
Aug 05

Palvella Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04